Sodium Cromoglycate (Cromolyn Sodium): The Complete, No-Stone-Unturned Master Resource
Most allergy conversations start and end with antihistamines.
Pop a pill, block a receptor, and hope the sneezing stops. But what if you could intercept the allergic explosion before it ever detonates?
That’s exactly where Sodium Cromoglycate lives—and why it has quietly been a game-changer for millions of patients with allergic rhinoconjunctivitis, asthma, mastocytosis, and food allergies for over five decades.
This isn’t a surface-level summary. We’re going deeper than any other “top 10” list on Google because Sodium Cromoglycate deserves a guide as thorough as its mechanism.
Whether you’re a patient, a compounding pharmacist, an allergist, or a pharmaceutical procurement specialist hunting for high-quality API, this post will leave no question unanswered.
Ready? Let’s get into the molecule that rewrites the allergy rulebook.
What is Sodium Cromoglycate, Natrium Cromoglycate and Cromoglycate Disodium, are they the same?
Yes—and the naming confusion is one of the first hurdles every researcher trips over. Let’s clear it up permanently.
Sodium Cromoglycate is the international nonproprietary name (INN) for the disodium salt of cromoglycic acid.
In the United States, it’s officially recognized as Cromolyn Sodium (USAN).
Natrium Cromoglycate is simply the Latinized chemical name used in some European pharmacopeias. Natrium b, meaning “sodium” in Latin, Cromoglycate Disodium and Disodium Cromoglycate are direct synonyms that describe the same chemical entity: 5,5′-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-4H-1-benzopyran-2-carboxylic acid] disodium salt.
To be absolutely precise:
CAS Number: 15826-37-6
Molecular Formula: C₂₃H₁₄Na₂O₁₁
Molecular Weight: 512.3 g/mol
All these terms refer to the identical mast cell stabilizer with the same clinical effects, whether you’re reading a British prescription labeled “Sodium Cromoglycate 2% eye drops” or an American vial of “Cromolyn Sodium Oral Concentrate.”
The product is the same; only the regulatory nomenclature differs.
Bottom line: If you see any of these names on a pharmacy shelf, an API certificate, or a clinical study, you’re looking at the only original mast cell stabilizer.
Is Sodium Cromoglycate an antihistamine?
This is the number-one myth that needs to die. Sodium Cromoglycate is NOT an antihistamine.
It doesn’t block histamine H1 or H2 receptors. It doesn’t reverse an allergic reaction already in progress, as diphenhydramine or cetirizine does.
So what is it? Sodium Cromoglycate belongs to a distinct class called mast cell stabilizers. Think of it this way:
Antihistamines = the fire extinguisher after the smoke is already billowing.
Sodium Cromoglycate = the fireproof safe that stops the spark from igniting the fumes.
It works prophylactically. When you administer it before allergen exposure, it prevents mast cells and basophils from degranulating—meaning that histamine, leukotrienes, prostaglandins, and a storm of inflammatory cytokines are never released in the first place.
This fundamental difference changes everything about dosing strategy, onset of action, and clinical expectations.
We’ll dissect exactly how it does this in the mechanism section, but for now, burn this into memory: Sodium Cromoglycate is not a substitute for an antihistamine in an acute allergic crisis.
It’s the shield you build weeks in advance so that a crisis never happens.
What is Sodium Cromoglycate used for?
Because it stops the allergic cascade at step zero, Sodium Cromoglycate’s utility stretches across multiple organ systems.
Let’s walk through the evidence-backed indications, formulation by formulation.
Allergic Conjunctivitis
The 2% and 4% ophthalmic solutions (often preserved with benzalkonium chloride or available in single-dose units) are first-line prophylactics for seasonal and perennial allergic conjunctivitis.
They reduce itching, tearing, and redness when used consistently throughout the allergy season. Unlike steroid eye drops, they carry zero risk of cataract or intraocular pressure rise, making them the go-to for long-term management.
Allergic Rhinitis
The nasal spray (typically a 4% solution) is indicated for the prevention and relief of sneezing, rhinorrhea, and nasal congestion.
It shines brightest when started two to four weeks before pollen season and used four to six times daily.
For patients who can’t tolerate intranasal steroids or want a non-steroidal option, cromoglycate nasal spray is a gentle yet effective choice—safe even during pregnancy (category B).
Asthma Prophylaxis
Inhaled Sodium Cromoglycate, delivered via a nebulizer solution (10 mg/mL) or a dry powder inhaler, was once a cornerstone of pediatric asthma maintenance therapy.
Current guidelines still recognize its role as a non-steroidal preventive alternative for mild persistent asthma, especially in children, where safety concerns about inhaled corticosteroids are paramount.
It reduces bronchial hyperresponsiveness and exercise-induced bronchoconstriction when taken regularly.
Food Allergy and Eosinophilic Esophagitis
The oral concentrate (100 mg/5 mL) is FDA-approved for systemic mastocytosis but is widely used off-label for food allergies and eosinophilic esophagitis (EoE).
Because only about 1% of an oral dose is absorbed systemically, it works topically on the GI mucosa, stabilizing gut mast cells.
Patients swallow a diluted solution before meals to reduce food-triggered abdominal pain, bloating, and diarrhea.
Systemic Mastocytosis
This is the flagship oral indication. In systemic mastocytosis, mast cells infiltrate organs and degranulate inappropriately, causing flushing, headache, GI distress, and even anaphylactoid episodes.
Oral Sodium Cromoglycate (Gastrocrom®) significantly reduces GI symptoms and improves quality of life.
Atopic Dermatitis and Other Off-Label Uses
Topical creams (compounded) containing 1–4% Sodium Cromoglycate have shown benefit in reducing pruritus in atopic dermatitis, though robust RCTs are limited.
Additionally, it’s been explored in inflammatory bowel disease, irritable bowel syndrome, and even as a suppressive therapy for chronic urticaria, with variable results.
The unifying thread: Sodium Cromoglycate is the master of local mast cell stabilization, and wherever mast cell degranulation drives the pathology, this molecule has a therapeutic rationale.
How does Sodium Cromoglycate work? (mechanism of action)
To appreciate the brilliance of Sodium Cromoglycate, you first need to understand the mast cell.
Mast cells are like ammunition depots packed with histamine, tryptase, chymase, TNF-α, and freshly synthesized leukotrienes.
When an allergen cross-links IgE antibodies on the mast cell surface, a signaling cascade triggers calcium influx and the explosive release of those granules—degranulation.
Sodium Cromoglycate does not act as a receptor antagonist. Instead, it stabilizes the mast cell membrane itself.
The current leading hypothesis centers on the inhibition of a specific chloride channel. Early studies with the khellin-derivative analog revealed that cromoglycate binds to a G protein-coupled receptor (GPR35) and also interferes with the intermediate-conductance Ca²⁺-activated K⁺ channel and the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. Still, the key mechanism appears to involve blocking Cl⁻ influx, which is necessary for mast cell activation.
Here’s the chain of events it halts:
Prevents chloride ion entry into the sensitized mast cell, which is required for the sustained calcium signaling that triggers granule movement to the membrane.
It inhibits the phosphorylation of moesin (a protein that tethers granules to the cytoskeleton), thereby immobilizing the histamine-containing vesicles.
Suppresses the release of preformed mediators (histamine, tryptase) and the de novo synthesis of lipid mediators (leukotriene C₄, prostaglandin D₂).
Dampens sensory nerve activation locally; some evidence suggests it reduces the release of substance P and other neuropeptides from airway C-fibers, adding an anti-neurogenic inflammation effect.
Crucially, Sodium Cromoglycate has no direct bronchodilator, antihistaminic, or anti-inflammatory steroid activity.
It will not reverse established bronchospasm or itching. Its power is entirely preventive, and its effects are tissue-localized—hence the need for multiple daily doses.
What are Sodium Cromoglycate side effects?
One of the reasons Sodium Cromoglycate has endured for 50+ years is its remarkable safety profile.
Because systemic absorption from topical routes (eye drops, nasal spray, inhalation) is minimal, and even oral absorption is less than 2%, systemic toxicity is rare.
However, local adverse events are formulation-specific.
Ophthalmic Use
Transient stinging or burning upon instillation (most common)
Mild conjunctival hyperemia
Blurred vision immediately after application (patients should wait before driving)
Nasal Spray
Nasal irritation, sneezing immediately after use
Epistaxis (nosebleed) infrequently
Unpleasant taste as it drains post-nasally
Inhalation (Nebulizer/DPI)
Cough, throat irritation
Bronchospasm (rare paradoxical reaction, more common with dry powder)
Wheezing—if this occurs, discontinue and reassess
Oral Administration
Initially, it may cause mild diarrhea, abdominal cramping, and nausea
These typically subside within 1–2 weeks of continued therapy
Very rarely: skin rash, joint pain, eosinophilic pneumonia
Systemic (Hypersensitivity)
Extremely rare but reported: anaphylaxis, angioedema, urticaria. Any patient developing systemic symptoms should discontinue immediately.
The beauty is, unlike corticosteroids, Sodium Cromoglycate does not cause immunosuppression, adrenal suppression, osteoporosis, or growth retardation—making it a cornerstone in pediatric and geriatric populations.
Sodium Cromoglycate Dosage and Administration
Dosing is entirely formulation-dependent, and adherence to frequency is the secret sauce for success.
Here’s your expert cheat sheet.
| Formulation | Concentration | Usual Dose & Frequency | Notes |
|---|---|---|---|
| Ophthalmic solution | 2% or 4% | 1–2 drops in each eye 4–6 times daily | Start 2 weeks before allergy season. Remove contact lenses before use; wait 15 minutes before reinserting. |
| Nasal spray | 4% (40 mg/mL) | 1 spray per nostril 4–6 times daily | Prime pump before first use. It can be used prophylactically and as needed, but yields the best results with regular dosing. |
| Nebulizer solution (inhalation) | 10 mg/mL (1% unit-dose vials) | 20 mg (1 vial) via nebulizer 4 times daily | May mix with bronchodilator solutions. Not for injection. |
| Dry powder inhaler (historic) | 20 mg/capsule | 1 capsule inhaled 4 times daily | Using a Spinhaler® device. Not available in all countries. |
| Oral concentrate (Gastrocrom®) | 100 mg/5 mL (20 mg/mL) | 200 mg (two 5 mL ampules) 4 times daily, 30 min before meals and at bedtime | Dilute in a glass of water. Start with a half dose in the first week to improve GI tolerance. |
| Compounded oral capsules | 100 mg | 200 mg 4 times daily | In the absence of a commercial oral solution, some pharmacies compound capsules; open and mix with water for a similar topical effect. |
Pediatric dosing: For children, the same concentrations apply, but frequency may be reduced to 3 times daily under physician guidance. Always consult a pediatric allergist.
Key principle: Because its half-life is short and it acts locally, skipping doses significantly reduces protection. Consistency matters more than the absolute milligram count.
How long does Sodium Cromoglycate stay in your system?
The pharmacokinetic fingerprint of Sodium Cromoglycate explains both its safety and its demanding dosing schedule.
Absorption: After inhalation, approximately 8% of the dose reaches the lungs and is rapidly absorbed into plasma. Oral bioavailability is around 1%—the rest stays in the GI lumen and is excreted unchanged. Ocular and nasal absorption are negligible.
Distribution: It does not bind significantly to plasma proteins. It is distributed primarily in extracellular fluid and does not readily cross the blood-brain barrier.
Metabolism: Sodium Cromoglycate is not metabolized. It circulates unchanged.
Elimination half-life: Approximately 80 minutes (range 60–90 minutes) in plasma. It is excreted equally in urine (as unchanged drug) and bile.
Duration of action: Tissue concentration at the mucosal level and the functional mast cell stabilization effect last considerably longer than the plasma half-life—clinical protection typically spans 4–6 hours per dose, which dictates the 4-times-daily regimen.
Answering the key question directly: Sodium Cromoglycate itself clears from the bloodstream within 5–6 half-lives (roughly 6–8 hours).
But its stabilizing effect on mast cells wears off once the drug concentration in the tissue drops, so after a single dose, your mast cells can begin to degranulate again within 6–8 hours.
This is why it demands continuous presence. There’s no lingering active metabolite, no accumulation, and no hangover.
Sodium Cromoglycate Precautions and Drug Interactions
While Sodium Cromoglycate is exceptionally clean, some nuances demand respect.
Precautions
Renal impairment: Though systemic absorption is minimal, the drug is renally excreted. In severe renal failure, accumulation is theoretically possible; dose reduction may be considered for oral therapy.
Pregnancy: FDA Pregnancy Category B. Animal studies show no fetal risk, and decades of use in pregnant women for allergic rhinitis and asthma have shown no increased teratogenicity. It remains one of the first-line prophylactic options.
Breastfeeding: Negligible amounts are excreted into breast milk because of poor oral absorption; considered compatible with lactation by the American Academy of Pediatrics.
Hepatic impairment: No dose adjustment necessary.
Acute asthma attack: Not a rescue medication. Do not use to abort an ongoing exacerbation.
Paradoxical bronchospasm: Discontinue immediately if inhalation triggers wheezing.
Drug Interactions
This is where Sodium Cromoglycate shines—clinically significant drug interactions are virtually nonexistent.
Because CYP450 enzymes do not metabolize it, it does not bind plasma proteins appreciably, and it does not alter gastric pH, it plays well with every class:
Antihistamines (loratadine, fexofenadine): safe co-administration, potentially additive prevention.
Inhaled beta-agonists (albuterol): routinely mixed in the same nebulizer cup.
Corticosteroids (inhaled, oral): no interference.
Antacids, PPIs, H2 blockers: no effect on GI action.
Food: oral cromoglycate should be taken before meals, but food does not impair its mucosal effect; it actually helps distribute it.
The single interaction to note: if mixing with a nebulized bronchodilator, ensure compatibility; albuterol and ipratropium are fine.
Do not mix with acetylcysteine (Mucomyst) as it may inactivate cromoglycate.
Sodium Cromoglycate vs. Antihistamines
This is the comparison that patients and practitioners constantly get wrong—and understanding it will make you the smartest person in the pharmacy aisle.
| Feature | Sodium Cromoglycate | Oral Antihistamines (Cetirizine, Loratadine, Fexofenadine, etc.) | Ketotifen (Ophthalmic/Systemic) |
|---|---|---|---|
| Class | Mast cell stabilizer | H1-receptor antagonist | An antihistamine with weak mast cell stabilizing property |
| Mechanism | Prevents mast cell degranulation; stops histamine release | Blocks histamine at H1 receptors after release | Blocks H1 receptors and inhibits calcium influx in mast cells |
| Onset of action | Prophylactic; full effect in 2–4 weeks of regular use | Within 1–2 hours, peak at 4–8 hours | Variable; antihistamine effect is rapid, mast stabilization takes days |
| Best for | Long-term prevention of allergic conjunctivitis, rhinitis, asthma, mastocytosis, and GI allergy | Acute symptom relief: sneezing, itching, urticaria | Allergic conjunctivitis prophylaxis (eye drops) and systemic allergy with a mast cell component |
| Sedation | None | None (second generation) / Drowsiness (first generation) | Drowsiness is common with oral ketotifen |
| Pregnancy safety | Category B | Category B (most second-gen) | Category C (oral) |
| Dosing frequency | 4–6 times daily | Once or twice daily | Twice daily (oral) or twice daily (eye drops) |
| Prescription status | Rx and OTC, depending on the country and formulation | Mostly OTC | Rx in the U.S. (oral), OTC ophthalmic in some countries |
The strategic takeaway: Sodium Cromoglycate does not compete with antihistamines; it complements them.
A patient with severe seasonal allergies might use cromoglycate nasal spray 4 times daily starting in February and add an oral antihistamine for breakthrough symptoms during peak pollen season.
In allergic conjunctivitis, cromoglycate eye drops prevent the itch, but an antihistamine drop like ketotifen (Zaditor) can abort acute itching if needed.
For mastocytosis, cromoglycate is often the foundation, with H1 and H2 antihistamines layered on top.
No other antihistamine offers the same preemptive mast cell stabilization.
If you want to prevent rather than react, Sodium Cromoglycate is the weapon of choice.
Compounding guidelines for Sodium Cromoglycate
Sodium Cromoglycate is an old molecule, but its commercial availability has fluctuated, making compounding pharmacies the unsung heroes for many patients.
If you’re a compounding pharmacist or a physician writing a prescription, here’s your practical roadmap.
Stability and Solubility
Sodium Cromoglycate is a freely water-soluble white to creamy-white powder. Solutions should be prepared with purified water and preserved appropriately.
It is photo-sensitive; protect it from excessive light. Store compounded products in amber glass or opaque plastic containers.
pH of a 1% aqueous solution is around 5.0–7.0. It is stable in the pH range of 4.0–8.0. Avoid extremes.
Autoclaving: It can withstand autoclaving at 121°C for 15 minutes without significant degradation, which is critical for sterile ophthalmic preparations.
Solution, it exhibits maximum stability at pH 5.0–6.0; the presence of phosphate buffer can accelerate degradation, so use citrate buffer or simply water with preservative.
Ophthalmic Drops (2% or 4%)
Formula for 10 mL of 2% Sodium Cromoglycate Ophthalmic Solution USP:
Sodium Cromoglycate: 200 mg
Benzalkonium chloride (preservative): 0.1 mg (0.001%) to 0.2 mg (0.002%)
Disodium edetate (stabilizer): 10 mg
Sodium chloride: q.s. to isotonicity (~80 mg)
Purified water: q.s. 10 mL
Adjust to pH 5.5–6.5 with sodium hydroxide/hydrochloric acid if needed. Sterilize by membrane filtration (0.22 micron) into sterile dropper bottles. Assign a beyond-use date of 28 days refrigerated, 14 days at room temperature.
Nasal Spray (4%)
Compounded similarly to a sterile ophthalmic preparation but with a nasal spray pump. Some formulations incorporate a small amount of propylene glycol to enhance mucosal retention, but water-based solutions are effective. No nasal-specific contraindications.
OrSolution (20 mg/mL equivalent to Gastrocrom®)
Sodium Cromoglycate: 2 g per 100 mL
Purified water: q.s.
Preservative: potassium sorbate 0.1% or sodium benzoate 0.1%
Flavoring optional.
This is not a sterile preparation but should be refrigerated and given a 14-day BUD unless stability testing supports a longer BUD.
Capsules for Topical GI Effect
Patients who can’t tolerate the liquid can use 100 mg of powder in a hard gelatin capsule, which should be opened and dissolved in water immediately before ingestion.
Compounding pure powder into capsules requires strict environmental controls to prevent cross-contamination with penicillin or hormones, as many patients with mastocytosis are hypersensitive.
Always verify your formula against USP-NF monographs and FDA guidance. Stability-indicating HPLC is recommended.
How long does Sodium Cromoglycate take to work?
This is the make-or-break question that determines compliance.
The answer depends on what you’re measuring:
Immediate local protection: When applied to the eye or nasal mucosa, mast-cell-stabilizing effects begin within minutes of the first dose. However, that initial dose only briefly covers the tissue surface.
Clinical symptom improvement: For seasonal allergic conjunctivitis or rhinitis, a noticeable reduction in symptoms typically occurs within 3–7 days with consistent 4-times-daily use, but the full prophylactic effect requires 2–4 weeks. This is why so many patients fail cromoglycate therapy—they quit before the fortress is built.
Asthma prophylaxis: A meta-analysis showed that a significant reduction in asthma symptoms and bronchodilator use occurs after approximately 4 weeks of regular inhaled cromoglycate.
Oral therapy for mastocytosis: GI symptom relief often begins within 1–2 weeks, with continued improvement over the next month. Diarrhea frequency may drop substantially.
Exercise-induced bronchoconstriction: If inhaled 15–30 minutes before exercise, it provides significant protection against a drop in FEV1, but maximum benefit is seen after a week of regular loading.
Pro tip: Counsel patients that this is not an instant-gratification drug. Set the expectation: “Use it religiously for one month, and then judge its effectiveness.” When used this way, its success rate rivals inhaled corticosteroids in some mild-to-moderate asthma cohorts.
Global Sourcing Tips for Sodium Cromoglycate API
For pharmaceutical manufacturers, distributors, and compounding facilities, securing a reliable, high-purity Active Pharmaceutical Ingredient (Sodium Cromoglycate API) is a strategic mission.
Sodium Cromoglycate API supply chains have unique quirks.
Quality Standards and Certifications
Insist on an API that meets:
USP (United States Pharmacopeia) or Ph. Eur. (European Pharmacopeia) monograph for Sodium Cromoglycate.
Alternatively, use BP (British Pharmacopeia) or IP (Indian Pharmacopeia) standards, but verify assay and impurity profiles.
A valid CEP (Certificate of Suitability) from the EDQM is gold for European importation.
Key Quality Parameters to Audit
Assay: 98.0–102.0% on anhydrous basis
Related substances (HPLC): individual impurities <0.1%, total <0.5%
Residual solvents: ensure compliance with ICH Q3C, particularly with methanol, acetone, and isopropyl alcohol used in synthesis.
Heavy metals: <10 ppm
Water content: typically 8–10% (cromoglycate disodium is hygroscopic and can exist as a hydrate)
Particle size: For dry powder inhaler formulations, particle size distribution (D90 <5 µm) is critical; for oral and ophthalmic solutions, particle size is irrelevant, but dissolution rate must be rapid.
Logistics and Storage
Store in well-closed containers, protected from light, below 30°C. Avoid humidity.
Sodium Cromoglycate is non-hazardous, non-flammable, but hygroscopic—ship with desiccant and a moisture barrier.
Lead times from India: 6–10 weeks after purchase order, including quality release and shipping.
Always request a recent batch analysis certificate and a statement of GMP compliance from the manufacturer. Consider a third-party audit by a qualified cGMP auditor.
Insider tip: When sourcing for ophthalmic-grade solution, require an additional bacterial endotoxin test (<0.5 EU/mg if intended for injectable or ophthalmic sterile product) and a particulate matter specification. The API must be sterile-filterable.
Frequently Asked Questions About Sodium Cromoglycate
Q: Can I use Sodium Cromoglycate eye drops with contact lenses?
A: Remove lenses before applying drops and wait at least 15 minutes before reinserting. Benzalkonium chloride, a preservative, can bind to soft lenses.
Q: Is cromoglycate safe for infants?
A: Yes. Pediatricians often use nebulized cromolyn sodium in infants with virus-induced wheeze, and oral cromoglycate in infants with severe food-protein-induced enterocolitis syndrome (FPIES) as an off-label, low-risk option.
Q: Why was the cromoglycate dry powder inhaler discontinued in the U.S.?
A: Commercial reasons, not safety. Nebulizer solutions remain available generically. International markets may still carry the inhaler.
Q: Can Sodium Cromoglycate be used for chronic idiopathic urticaria?
A: Limited evidence; some case series show benefit as an add-on to antihistamines, but it’s not a standard therapy.
Q: Is there a risk of tachyphylaxis?
A: No. Unlike decongestant nasal sprays, cromoglycate does not lose effectiveness with prolonged use. Patients can rely on it for entire seasons.
Conclusion
Sodium Cromoglycate is the quiet giant of allergy prevention—a molecule born from an ancient herbal remedy, refined into a precision mast cell stabilizer that sidesteps the entire histamine circus.
From the naming confusion of natrium cromoglycate and cromoglycate disodium, to its tissue-specific mechanisms, to the nuances of compounding it into life-changing formulations, we’ve covered ground that most resources barely scratch.
If you take away one thing, let it be this: Sodium Cromoglycate is not a rescue pill.
It’s a commitment to preventive, topical allergy control that rewards patience with profound, steroid-sparing results.
For the patient with miserable seasonal eyes, the child with wheeze, the mastocytosis warrior, or the formulation scientist searching for that perfect GMP API batch, Sodium Cromoglycate remains as relevant in 2025 as the day it was synthesized.
Ready to integrate Sodium Cromoglycate into your protocol, pharmacy, or supply chain?
Bookmark this guide, share it with your team, and never accept a superficial search result again. The mast cell stabilizer revolution starts before the reaction—now you know exactly how to lead it.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
